OPT Congress
4th Annual Oligonucleotide & Precision Therapeautics
March 2019
Cambridge
HGF Patent Director Alison Gallafent will be presenting “siRNA science journey as reflected by the patent literature” at the 4th Annual Oligonucleotide & Precision Therapeautics March 26-28 2019 in Cambridge.
To complement the 4th annual Oligonucleotide Discover and Delivery conference there will also be a 2 day program dedicated to Oligonucleotide CMC and Regulatory Strategies plus two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair.
The OPT congress brings together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers to provide a unique opportunity to discuss advances in next generation oligonucleotide therapies throughout the drug development process.
Patent Director Alison Gallafent will be presenting “siRNA science journey as reflected by the patent literature”.
Starting with patents that initially reflected manufacturing constraints, moving to patents reflecting greater understanding of chemical modifications, and later product specific patents. Advantages and potential challenges are associated with patent protection at the different stages of this journey. Close interaction between Research and Attorney can help to address potential challenges.
For more information please see here